Importance of long non-coding RNAs in the pathogenesis, diagnosis, and treatment of prostate cancer

Long non-coding RNAs (lncRNAs) are regulatory transcripts with essential roles in the pathogenesis of almost all types of cancers, including prostate cancer. They can act as either oncogenic lncRNAs or tumor suppressor ones in prostate cancer. Small nucleolar RNA host genes are among the mostly assessed oncogenic lncRNAs in this cancer. PCA3 is an example of oncogenic lncRNAs that has been approved as a diagnostic marker in prostate cancer. A number of well-known oncogenic lncRNAs in other cancers such as DANCR, MALAT1, CCAT1, PVT1, TUG1 and NEAT1 have also been shown to act as oncogenes in prostate cancer. On the other hand, LINC00893, LINC01679, MIR22HG, RP1-59D14.5, MAGI2-AS3, NXTAR, FGF14-AS2 and ADAMTS9-AS1 are among lncRNAs that act as tumor suppressors in prostate cancer. LncRNAs can contribute to the pathogenesis of prostate cancer via modulation of androgen receptor (AR) signaling, ubiquitin-proteasome degradation process of AR or other important signaling pathways. The current review summarizes the role of lncRNAs in the evolution of prostate cancer with an especial focus on their importance in design of novel biomarker panels and therapeutic targets.

Automated summary

Long non-coding RNAs (lncRNAs) play essential roles in the pathogenesis of prostate cancer, acting as either oncogenic or tumor suppressor lncRNAs. Prominent oncogenic lncRNAs such as PCA3, DANCR, MALAT1, CCAT1, PVT1, TUG1, and NEAT1 have been identified. Conversely, tumor suppressor lncRNAs, including LINC00893, LINC01679, MIR22HG, RP1-59D14.5, MAGI2-AS3, NXTAR, FGF14-AS2, and ADAMTS9-AS1, have also been implicated. LncRNAs modulate androgen receptor signaling, AR degradation, and other signaling pathways in prostate cancer.